Chill out Harvett. It's phase 1 mate.
I don't know if you seriously believe what you are throwing up here, or are perhaps limited in your knowlege of pharma regs, drug development processes and the Herculean requirements involved in putting these formulations into, well...people. Or maybe "google" was playing up today?
These results are promising enough, certainly, to continue to phases II > on.
6 month progression free survival endpoints / SD (stable disease) for cytostatic therapies have delivered numerous billion dollar therapies.
Could this be one? Far too early to tell.
DYOR out there ppl.
Ann: Veyonda and Radiotherapy Delivers Clinical Benefits, page-19
Add NOX (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
11.5¢ |
Change
0.010(9.52%) |
Mkt cap ! $30.68M | |||
| Open | High | Low | Value | Volume |
| 10.5¢ | 11.5¢ | 10.5¢ | $11.79K | 102.8K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 25000 | 11.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 12.0¢ | 73160 | 4 |
View Market Depth
| Last trade - 13.18pm 01/10/2024 (20 minute delay) ? |
| NOX (ASX) Chart |